Gaballah, A., Shafik, A., Elhusseiny, K., Ashraf, M. (2018). Chemotherapy-Induced Peripheral Neuropathy in Egyptian Patients: Single Institution Retrospective Analysis. Asian Pacific Journal of Cancer Prevention, 19(8), 2223-2227. doi: 10.22034/APJCP.2018.19.8.2223
Ahmed Gaballah; Amr Shafik; Khaled Elhusseiny; Mai Ashraf. "Chemotherapy-Induced Peripheral Neuropathy in Egyptian Patients: Single Institution Retrospective Analysis". Asian Pacific Journal of Cancer Prevention, 19, 8, 2018, 2223-2227. doi: 10.22034/APJCP.2018.19.8.2223
Gaballah, A., Shafik, A., Elhusseiny, K., Ashraf, M. (2018). 'Chemotherapy-Induced Peripheral Neuropathy in Egyptian Patients: Single Institution Retrospective Analysis', Asian Pacific Journal of Cancer Prevention, 19(8), pp. 2223-2227. doi: 10.22034/APJCP.2018.19.8.2223
Gaballah, A., Shafik, A., Elhusseiny, K., Ashraf, M. Chemotherapy-Induced Peripheral Neuropathy in Egyptian Patients: Single Institution Retrospective Analysis. Asian Pacific Journal of Cancer Prevention, 2018; 19(8): 2223-2227. doi: 10.22034/APJCP.2018.19.8.2223
Chemotherapy-Induced Peripheral Neuropathy in Egyptian Patients: Single Institution Retrospective Analysis
Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Receive Date: 05 February 2018,
Revise Date: 09 June 2018,
Accept Date: 16 July 2018
Abstract
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a major toxicity that requires treatment modification or cessation and worsens patients’ quality of life. Its incidence is 30–40%. Occurrence and severity depend on treatment- and patient-related factors. The symptoms are self-limiting with recovery rate about 50%. Methods: This retrospective analysis took place in our chemotherapy unit. We included patients treated between January 2014 and December 2015. Results: 250 patients were eligible. 53 received paclitaxel, 78 received docetaxel, 64 received cisplatin and 55 received oxaliplatin. Mean age was 50.11 years. Frequency of CIPN was 46.8% (Grade I 70.9%, GII 24.7%, GIII 4.4%). It was 74% with oxaliplatin, 73.5% with paclitaxel, 35.9% with cisplatin and 17.9% with docetaxel. After median of 6 months 24% of patients recovered completely. No significant correlation between occurrence of CIPN and age (p = 0.781), while was significant with cisplatin (p = 0.043). Diabetic patients had higher incidence (p = 0.007). With cisplatin, median cumulative dose of 450 mg/m2 and ≥ 6 cycles had higher incidence of CIPN (p 0.006 and 0.010; respectively). With oxaliplatin, none was correlated with CIPN frequence. With paclitaxel, CIPN was more frequent if ≥ 4 cycles were received (p = 0.005). With docetaxel, > 4 cycles or cumulative dose ≥ 360 mg/m2 had higher occurrence of GII CIPN (p < 0.001 for both). Conclusion: CIPN is common problem that affects patients’ quality of life and leads to treatment interruption. There are many factors affecting its incidence and severity.
Top